01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Inverse relationship of Rho kinase and myosin-light chain kinase expression in the aging human detrusor smooth muscle
- Zeitschrift:
- BMC Urology > Ausgabe 1/2015
Competing interests
Authors’ contributions
Background
Methods
Preparation of detrusor smooth muscle strips
No.
|
Age
|
Sex
|
Diagnosis and cystectomy indication
|
Type of surgery
|
History
|
---|---|---|---|---|---|
1
|
68
|
m
|
Bladder cancer G2 pT2b pN0 (0/9) L0 F0 R0 cM0
|
Radical cystectomy/neobladder
|
S/P 1× TUR bladder G3 pT2a
|
2
|
66
|
w
|
Bladder cancer pT1 G3 pN0 L0 V0 R0 M0
|
Radical cystectomy/Mainz Pouch I
|
S/P 1× TUR bladder G2 pT1 and Cis
|
3
|
61
|
m
|
Bladder cancer pT3a pN0 cMx R0 G3 Carcinoma left renal pelvis pT2 pN3 cMx R1 G3 Prostate cancer pT1a pN0 cMx Gleason 2 + 3 = 5
|
Radical cystectomy and nephroureterectomy left/ileal conduit
|
S/P 11× TUR bladder G2 pTa and Cis, at least pT2 G3
|
4
|
80
|
m
|
Bladder cancer pT2b (is) pN0 cM0 R0 L0 V0 G3 Prostate cancer: pT2a pN0 (0/13) R0 L0 V0 Gleason: 3 + 3
|
Radical cystectomy/ileal conduit
|
S/P 1 × TUR bladder G3, pT2a
|
5
|
68
|
m
|
Bladder cancer pT1 (is) pN0 (0/12) G3 R0 L0 V0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR bladder pT1 G3 and pTa G2
|
6
|
62
|
m
|
Bladder cancer pT2b (is), pNo (0/20) G3 R0 L1 V0 cM0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR bladder pT2a G3
|
7
|
73
|
m
|
Bladder cancer (with adenoid vegetations) G3 pT1 pN0 (0/11) L0 V0 R0 M0 Prostate cancer G2 pT2c PN0 L0 V0 R0 M0 Gleason 3 + 2 = 5
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-prostate (no malignancy) S/P 1x TUR-bladder pT1 G3
|
8
|
46
|
m
|
Bladder cancer G2 pTa pN0 (0/18) L0 V0 R0 M0 and renal failure (on dialysis)
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder (necrotic urothelial carcinoma)
|
9
|
84
|
w
|
Bladder cancer G4, pT4a pN0 (0/9) M1 (PER) L1 V0 R1 (with sarcomatoid differentiation)
|
Radical cystectomy with cutaneous ureterostomy
|
S/P 6× TUR-bladder rpTa-1 G1-2, at least G3 pT2
|
10
|
50
|
m
|
Prostate cancer 4 + 5 = 9; pT4 pN1 (8/22) L0 V0 R0 cM0 (with bladder infiltration)
|
Radical cystectomy/ileal conduit
|
S/P prostate biopsy pT1c Gleason 5 + 4 = 9 and suprapubic catheter after overflow bladder
|
11
|
60
|
m
|
Bladder cancer pT1 pN0 cM0 R0 G2 (high grade)
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR bladder pTa G2 and pT1 G2
|
12
|
80
|
w
|
Bladder cancer pT1 pN0 cM0 R0 G2 (high grade)
|
Radical cystectomy with urethrectomy/ileal conduit
|
no history available
|
13
|
68
|
m
|
Neurogenic bladder (contracted bladder) Prostate cancer pT2c R0 L0 V0; Gleason 3 + 3 = 6
|
Radical cystectomy/ ileal conduit
|
Incomplete paraplegia Th4 Polyneuropathy due to alcoholism S/P suprapubic catheter
|
14
|
74
|
m
|
Bladder cancer pT1 pN2 (2/17) G3 R0 L1 V0
|
Radical cystectomy/ileal conduit
|
no history available
|
15
|
59
|
m
|
Bladder cancer pT3b pN2 (2/12) G3 R0 L1 V0
|
Radical cystectomy/neobladder
|
S/P 2× TUR-bladder pT1 G2-3 (adenocarcinoma)
|
16
|
60
|
m
|
Bladder cancer pTis pN0 (0/24) R0 M0 Renal pelvic cancer pT3 G2 R0 N0 L0 V0
|
Radical cystectomy/ileal conduit and left nephrectomy
|
S/P 1×TUR-bladder pTis with urothelial carcinoma G2-3 and urothelial carcinoma left renal pelvis G1 pTa
|
17
|
57
|
m
|
Bladder cancer G3 pT1 pN0 (0/26) L0 V0 R0 cM0
|
Radical cystectomy/neobladder
|
S/P 3× TUR-bladder G3, pTa and mrpTis
|
18
|
71
|
m
|
Bladder cancer G3 pT3b pN2 (9/20) L1 V1 R0 cM1
|
Radical cystectomy/ileal conduit
|
S/P 7× TUR-bladder pTa G2 and pT1G3 and rpT1G3
|
19
|
74
|
m
|
Bladder cancer G3 pT2a pN0 (0/5) L0 V0 R0 cM0 Prostate cancer pT2 pN0 M0 G2
|
Radical cystectomy/ ileal conduit
|
S/P 1× TUR-bladder mpT1 G3
|
20
|
72
|
m
|
Bladder cancer pTX pN2 (3/12) G3 R0 cM0
|
Radical cystectomy/ileal conduit
|
S/P TUR-bladder T2a G2-3
|
21
|
75
|
m
|
Bladder cancer G3 pT3b pN0 (0/14) L1 V0 R1 cM0 Prostate cancer Gleason: 4 + 5 = 9; G3 pT2c pN0 L0 V0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder T2 G3, renal failure
|
22
|
56
|
m
|
Bladder cancer G3 pT3a pN3 L1 V1 pM1 (LYM) Prostate cancer Gleason 2 + 3 = 5; G2 pT2c
|
Radical cystectomy/ileal conduit
|
S/P TUR-bladder T2 G3
|
23
|
77
|
m
|
Bladder cancer G3 pT1 pN0 (0/13) L0 V0 R0 cM0 Prostate cancer Gleason 3 + 4 = 7; G3 pT2a pN0 L0 V0 R0 M0
|
Radical cystectomy/ileal conduit
|
S/P 4× TUR-bladder rpT1G2 and pTa G2
|
24
|
84
|
m
|
Bladder cancer G3 pT2a pN0 (0/17) L0 V0 R0 cM0
|
Radical cystectomy/ileal conduit
|
S/P 3× TUR-bladder pTa G1-2 and at least pT2 G3
|
25
|
56
|
w
|
Bladder cancer pT1 (is) pN0 cM0 R0 G3 V0 L0
|
Radical cystectomy/Mainz Pouch I
|
S/P 1× TUR-bladder pT1 G3 and mpTis
|
26
|
80
|
w
|
Bladder cancer G3 pT1 (is) pN0 (0/21) Mx V0 L0 R0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder G3 pT1
|
27
|
55
|
w
|
Urethra cancer pT2 pN0 (0/22) G2 R0 L0 V0 cM0 (squamous cell carcinoma)
|
Radical cystectomy/Mainz Pouch I
|
S/P 1× TUR-urethra (squamous cell carcinoma pTis)
|
28
|
52
|
m
|
Bladder cancer pT3b pN2 (9/20) M1 (lymph) G3 R0 L1 V0 Prostate cancer pT2c pN0 cM0 R0 L0 V0 Gleason 3 + 4 = 7
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder G3 pT2
|
29
|
56
|
m
|
Bladder cancer pT3a pN0 (0/25) G3 R0 L1 V0 cM0
|
Radical cystectomy/neobladder
|
S/P 1× TUR-bladder G3 pT2 (is)
|
30
|
56
|
m
|
Prostate cancer Gleason 4 (80 %) + 3 = 7; G3 pT4 pN1 (4/12) L1 V0 R1 cM0 (with bladder infiltration)
|
Radical cystectomy/ileal conduit
|
no history available
|
31
|
76
|
w
|
Bladder cancer pT3b pN1 (1/18) G3 R0 L1 V0 cM0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder pT2 G3 S/P TFS (tissue fixation system - sacrouterine ligament)
|
32
|
70
|
m
|
Bladder cancer G2 pT3b pN0 (0/15) MX V0 L0 R0 (squamous cell carcinoma)
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder pT2 G3 (squamous cell carcinoma)
|
33
|
81
|
m
|
Bladder cancer ypTis pN0 (0/17) R0 cM0 Prostate cancer pT2a pN0 (0/17) R0 L0 V0, Gleason 3 + 3 = 6
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder pT1 (m, is) G2-3
|
34
|
63
|
m
|
Cancer of prostatic duct
|
Radical cystectomy/ileal conduit
|
S/P mult. TUR-bladder (carcinoma in prostatic duct)
|
35
|
74
|
m
|
Bladder cancer pT1 pN0 cM0 R0 G2 V0 L0
|
Radical cystectomy/neobladder
|
S/P1× TUR-bladder at least pT1 G3
|
36
|
59
|
m
|
Bladder cancer G3 pT2(is) pN2 (3/25) pM1 (lymph) L1 V1 R0 Prostate adenocarcinoma G2, Gleason 3 + 3 = 6, pT2b pN0 L0 V0 Pn1 R0
|
Radical cystectomy/neobladder
|
S/P1× TUR-bladder mpT2 (is) L1 G2-3
|
37
|
76
|
m
|
Bladder cancer and prostate cancer pT2c pN0 (0/18) R0 L0 V0 pN0, Gleason: 3 + 3 = 6
|
Radical cystectomy/ileal conduit
|
no history available
|
38
|
68
|
w
|
Neurogenic bladder, multiple sclerosis
|
Cystectomy/ileal conduit
|
Chronic pelvic pain, detrusor hyperactivity, incomplete spastic paraplegia
|
39
|
51
|
m
|
Bladder cancer pT4a (is) pN0 (0/16) G3 R0 L1 V0 cM0
|
Radical cystectomy/ileal conduit
|
S/P 1× TUR-bladder G3, at least pT1 Nx M0 Nicotine abuse
|
40
|
84
|
m
|
Bladder cancer G3 pT3a (is) pN0 (0/11) L0 V1 R0 cM0 Prostate adenocarcinoma Gleason 4 + 4 = 8, G3 pT2c pN0 L0 V0 R0 cM0
|
Radical cystectomy/ileal conduit
|
no history available
|
41
|
74
|
m
|
Bladder cancer G3 pT1 pN0 (0/18) L0 V0 R0 M0
|
Radical cystectomy/ileal conduit
|
S/P G3, at least pT1 and carcinoma in situ.
|
Quantitative RT-PCR analysis
Gene name
|
Forward primer
|
Reverse primer
|
PCR product
|
---|---|---|---|
ROCK1
|
AAAATTGTGTGAGGAGGACATGG
|
TTCATCCCAACATTCTTGGATCT
|
279 bp
|
ROCK2
|
GCAATGCGGTAAAAAGCGA
|
GGGAATCATGGTGTGACCAA
|
217 bp
|
MLCK
|
GTCTTATGTTATCTTCCATTCTA
|
TATAATAAACTGTGGCAATACTG
|
156 bp
|
GAPDH
|
AGAAGGCTGGGGCTCATTTG
|
AGGGGCCATCCACAGTCTTC
|
285 bp
|
Statistics
Results
Target gene
|
Reference genes
|
||
---|---|---|---|
GAPDH
|
ACTB
|
PGK1
|
|
ROCK1 (
n
= 41)
|
−0.0043
|
−0.1584
|
−0.0732
|
only male subjects (
n = 33)
|
−0.0375
|
−0.1577
|
−0.1596
|
ROCK2 (
n
= 41)
|
−0.1436
|
−0.0733
|
0.0812
|
only male subjects (
n = 33)
|
−0.0884
|
−0.0404
|
0.0810
|
MLCK (
n
= 21)
|
0.0201
|
−0.4151*
|
0.0593
|
only male subjects (
n = 18)
|
0.2899
|
−0.3549
|
0.0371
|
ROCK1-to-MLCK ratio (
n
= 21)
|
−0.2996
|
−0.3325
|
−0.3839*
|
only male subjects (
n = 18)
|
−0.2802
|
−0.4389*
|
−0.5364*
|
ROCK2-to-MLCK ratio (
n
= 21)
|
−0.4757*
|
−0.4427*
|
−0.4298*
|
only male subjects (
n = 18)
|
−
0.4246*
|
−
0.4694*
|
−
0.5854**
|
ROCK-to-MLCK ratio (
n
= 21)
|
−0.5297**
|
−0.4352*
|
−0.5181**
|
only male subjects (
n = 18)
|
−
0.4625*
|
−
0.4981*
|
−
0.6126**
|